- Home
- NRGV vs CLLS Comparison
NRGV vs CLLS Comparison
Compare NRGV & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- CLLS
- Stock Information
- Founded
- NRGV 2017
- CLLS 1999
- Country
- NRGV United States
- CLLS France
- Employees
- NRGV N/A
- CLLS N/A
- Industry
- NRGV Industrial Machinery/Components
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- CLLS Health Care
- Exchange
- NRGV Nasdaq
- CLLS Nasdaq
- Market Cap
- NRGV 135.4M
- CLLS 240.2M
- IPO Year
- NRGV N/A
- CLLS 2007
- Fundamental
- Price
- NRGV $0.79
- CLLS $2.26
- Analyst Decision
- NRGV Hold
- CLLS Buy
- Analyst Count
- NRGV 5
- CLLS 2
- Target Price
- NRGV $2.25
- CLLS $8.00
- AVG Volume (30 Days)
- NRGV 387.5K
- CLLS 25.9K
- Earning Date
- NRGV 11-05-2024
- CLLS 11-04-2024
- Dividend Yield
- NRGV N/A
- CLLS N/A
- EPS Growth
- NRGV N/A
- CLLS N/A
- EPS
- NRGV N/A
- CLLS N/A
- Revenue
- NRGV $301,970,000.00
- CLLS $19,635,000.00
- Revenue This Year
- NRGV N/A
- CLLS $271.02
- Revenue Next Year
- NRGV $544.38
- CLLS $33.48
- P/E Ratio
- NRGV N/A
- CLLS N/A
- Revenue Growth
- NRGV 97.21
- CLLS N/A
- 52 Week Low
- NRGV $0.78
- CLLS $0.96
- 52 Week High
- NRGV $3.22
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- NRGV 40.92
- CLLS 50.23
- Support Level
- NRGV $0.78
- CLLS $2.19
- Resistance Level
- NRGV $0.92
- CLLS $2.40
- Average True Range (ATR)
- NRGV 0.08
- CLLS 0.10
- MACD
- NRGV -0.01
- CLLS -0.01
- Stochastic Oscillator
- NRGV 4.79
- CLLS 37.74
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.